432 related articles for article (PubMed ID: 30049651)
1. Pyridoxal 5'-phosphate and related metabolites in hypophosphatasia: Effects of enzyme replacement therapy.
Akiyama T; Kubota T; Ozono K; Michigami T; Kobayashi D; Takeyari S; Sugiyama Y; Noda M; Harada D; Namba N; Suzuki A; Utoyama M; Kitanaka S; Uematsu M; Mitani Y; Matsunami K; Takishima S; Ogawa E; Kobayashi K
Mol Genet Metab; 2018 Sep; 125(1-2):174-180. PubMed ID: 30049651
[TBL] [Abstract][Full Text] [Related]
2. Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy.
Ishiguro T; Sugiyama Y; Ueda K; Muramatsu Y; Tsuda H; Kotani T; Michigami T; Tachikawa K; Akiyama T; Hayakawa M
Brain Dev; 2019 Sep; 41(8):721-725. PubMed ID: 31000369
[TBL] [Abstract][Full Text] [Related]
3. Pyridoxal 5'-phosphate, pyridoxal, and 4-pyridoxic acid in the paired serum and cerebrospinal fluid of children.
Akiyama T; Hayashi Y; Hanaoka Y; Shibata T; Akiyama M; Tsuchiya H; Yamaguchi T; Kobayashi K
Clin Chim Acta; 2017 Sep; 472():118-122. PubMed ID: 28778380
[TBL] [Abstract][Full Text] [Related]
4. Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults.
Shajani-Yi Z; Ayala-Lopez N; Black M; Dahir KM
Bone; 2022 Oct; 163():116504. PubMed ID: 35878747
[TBL] [Abstract][Full Text] [Related]
5. Vitamin B
Whyte MP; May JD; McAlister WH; Burgener K; Cortez SR; Kreienkamp R; Castro O; Verzola R; Zavala AS; McPherson CC; Gottesman GS; Ericson KL; Coburn SP; Arbelaez AM
Bone; 2021 Sep; 150():116007. PubMed ID: 34000433
[TBL] [Abstract][Full Text] [Related]
6. Pyridoxine challenge reflects pediatric hypophosphatasia severity and thereby examines tissue-nonspecific alkaline phosphatase's role in vitamin B
Whyte MP; Zhang F; Mack KE; Wenkert D; Gottesman GS; Ericson KL; Cole JT; Coburn SP
Bone; 2024 Apr; 181():117033. PubMed ID: 38307176
[TBL] [Abstract][Full Text] [Related]
7. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene.
Baumgartner-Sigl S; Haberlandt E; Mumm S; Scholl-Bürgi S; Sergi C; Ryan L; Ericson KL; Whyte MP; Högler W
Bone; 2007 Jun; 40(6):1655-61. PubMed ID: 17395561
[TBL] [Abstract][Full Text] [Related]
8. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Kishnani PS; Rockman-Greenberg C; Rauch F; Bhatti MT; Moseley S; Denker AE; Watsky E; Whyte MP
Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866
[TBL] [Abstract][Full Text] [Related]
9. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa.
Kishnani PS; Del Angel G; Zhou S; Rush ET
Mol Genet Metab; 2021 May; 133(1):113-121. PubMed ID: 33814268
[TBL] [Abstract][Full Text] [Related]
10. Common Variants at Putative Regulatory Sites of the Tissue Nonspecific Alkaline Phosphatase Gene Influence Circulating Pyridoxal 5'-Phosphate Concentration in Healthy Adults.
Carter TC; Pangilinan F; Molloy AM; Fan R; Wang Y; Shane B; Gibney ER; Midttun Ø; Ueland PM; Cropp CD; Kim Y; Wilson AF; Bailey-Wilson JE; Brody LC; Mills JL
J Nutr; 2015 Jul; 145(7):1386-93. PubMed ID: 25972531
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy for congenital hypophosphatasia allows for surgical treatment of related complex craniosynostosis: a case series.
Kosnik-Infinger L; Gendron C; Gordon CB; Pan BS; van Aalst JA; Vogel TW
Neurosurg Focus; 2015 May; 38(5):E10. PubMed ID: 25929963
[TBL] [Abstract][Full Text] [Related]
12. Measurement of pyridoxal 5'-phosphate, pyridoxal, and 4-pyridoxic acid in the cerebrospinal fluid of children.
Akiyama T; Akiyama M; Hayashi Y; Shibata T; Hanaoka Y; Toda S; Imai K; Hamano SI; Okanishi T; Yoshinaga H; Kobayashi K
Clin Chim Acta; 2017 Mar; 466():1-5. PubMed ID: 28040557
[TBL] [Abstract][Full Text] [Related]
13. Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges.
Whyte MP
J Bone Miner Res; 2017 Apr; 32(4):667-675. PubMed ID: 28084648
[TBL] [Abstract][Full Text] [Related]
14. Enzyme Replacement Therapy in Hypophosphatasia.
Uçaktürk SA; Elmaogullari S; Ünal S; Gönülal D; Mengen E
J Coll Physicians Surg Pak; 2018 Sep; 28(9):S198-S200. PubMed ID: 30173697
[TBL] [Abstract][Full Text] [Related]
15. Hypophosphatasia: Vitamin B
Whyte MP; Zhang F; Wenkert D; Mack KE; Bijanki VN; Ericson KL; Coburn SP
Bone; 2022 Jan; 154():116204. PubMed ID: 34547524
[TBL] [Abstract][Full Text] [Related]
16. Mutational and biochemical findings in adults with persistent hypophosphatasemia.
McKiernan FE; Dong J; Berg RL; Scotty E; Mundt P; Larson L; Rai I
Osteoporos Int; 2017 Aug; 28(8):2343-2348. PubMed ID: 28401263
[TBL] [Abstract][Full Text] [Related]
17. Serum B
Huang JY; Butler LM; Midttun Ø; Koh WP; Ueland PM; Wang R; Jin A; Gao YT; Yuan JM
Cancer Causes Control; 2016 Dec; 27(12):1447-1456. PubMed ID: 27830400
[TBL] [Abstract][Full Text] [Related]
18. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.
Whyte MP; Rockman-Greenberg C; Ozono K; Riese R; Moseley S; Melian A; Thompson DD; Bishop N; Hofmann C
J Clin Endocrinol Metab; 2016 Jan; 101(1):334-42. PubMed ID: 26529632
[TBL] [Abstract][Full Text] [Related]
19. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.
Bowden SA; Adler BH
Osteoporos Int; 2018 Feb; 29(2):511-515. PubMed ID: 29046930
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial.
Kitaoka T; Tajima T; Nagasaki K; Kikuchi T; Yamamoto K; Michigami T; Okada S; Fujiwara I; Kokaji M; Mochizuki H; Ogata T; Tatebayashi K; Watanabe A; Yatsuga S; Kubota T; Ozono K
Clin Endocrinol (Oxf); 2017 Jul; 87(1):10-19. PubMed ID: 28374482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
